<DOC>
	<DOCNO>NCT00818584</DOCNO>
	<brief_summary>This study evaluate pharmacokinetics safety intravenous micafungin neonate suspect candida infection</brief_summary>
	<brief_title>An Open-Label Study Safety Pharmacokinetics Repeated-Dose Micafungin Neonates</brief_title>
	<detailed_description>Subjects stratify weight receive one two dos study drug</detailed_description>
	<mesh_term>Micafungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Informed consent HIPAA authorization infant 's parent legally authorize representative must obtain prior study entry Infant sufficient venous access permit study drug dose Infant suspect systemic Candida infection appropriate culture ( blood without urine/CSF ) obtain time study entry Infant history anaphylaxis , hypersensitivity , serious reaction echinocandin class antifungal Infant receive echinocandin within one month prior study entry Infant concomitant medical condition , opinion investigator and/or medical advisor , may create unacceptable additional risk Infant life expectancy le 96 hour</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Days</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Micafungin</keyword>
	<keyword>Candida</keyword>
	<keyword>Neonates</keyword>
	<keyword>Mycamine</keyword>
	<keyword>FK463</keyword>
</DOC>